Bifunctional Janus Particles as Multivalent Synthetic Nanoparticle Antibodies (SNAbs) for Selective Depletion of Target Cells
Source abstract
Abstract
Monoclonal antibodies (mAb) have had a transformative impact on treating cancers and immune disorders. However, their use is limited by high development time and monetary cost, manufacturing complexities, suboptimal pharmacokinetics, and availability of disease-specific targets. To address some of these challenges, we developed an entirely synthetic, multivalent, Janus nanotherapeutic platform, called Synthetic Nanoparticle Antibodies (SNAbs). SNAbs, with phage-display-identified cell-targeting ligands on one "face" and Fc-mimicking ligands on the opposite "face", were synthesized using a custom, multistep, solid-phase chemistry method. SNAbs efficiently targeted and depleted myeloid-derived immune-suppressor cells (MDSCs) from mouse-tumor and rat-trauma models, ex vivo. Systemic injection of MDSC-targeting SNAbs efficiently depleted circulating MDSCs in a mouse triple-negative breast cancer model, enabling enhanced T cell and Natural Killer cell infiltration into tumors. Our results demonstrate that SNAbs are a versatile and effective functional alternative to mAbs, with advantages of a plug-and-play, cell-free manufacturing process, and high-throughput screening (HTS)-enabled library of potential targeting ligands.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Nanoscale Materials, Argonne National Laboratory, Lemont, Illinois 60517, United States
School of Medicine, University of Pittsburgh, 3550 Terrace St., Pittsburgh, Pennsylvania 15213, United States
Orthopaedics Department, Emory University, Atlanta, Georgia 30322, United States
Research Service, Atlanta VA Medical Center, Decatur, Georgia 30033, United States
Funding
Georgia Institute of Technology · Giglio Breast Cancer Innovation Fund · Children and Athletes Regenerative Medicine Foundation
References (68)
Show source-provided references
1. 10.1056/NEJMoa120069410.1056/NEJMoa1200694 ↗
2. 10.1038/nrc323610.1038/nrc3236 ↗
3. 10.1111/j.1476-5381.2009.00190.x10.1111/j.1476-5381.2009.00190.x ↗
4. 10.1038/jid.2013.52110.1038/jid.2013.521 ↗
5. 10.7150/thno.1171110.7150/thno.11711 ↗
6. 10.3389/fimmu.2017.0128710.3389/fimmu.2017.01287 ↗
7. 10.1016/j.it.2016.01.00410.1016/j.it.2016.01.004 ↗
8. 10.1038/nm.339410.1038/nm.3394 ↗
9. 10.1021/am505510m10.1021/am505510m ↗
10. 10.1021/acs.chemmater.6b0532210.1021/acs.chemmater.6b05322 ↗
11. 10.1016/j.ccr.2020.21346710.1016/j.ccr.2020.213467 ↗
12. 10.1016/j.ijpharm.2019.01.02010.1016/j.ijpharm.2019.01.020 ↗
13. 10.1021/acs.nanolett.7b0382910.1021/acs.nanolett.7b03829 ↗
14. 10.1002/smll.20190496010.1002/smll.201904960 ↗
15. 10.1039/C6AN00325G10.1039/C6AN00325G ↗
16. 10.1039/c2cs35032g10.1039/c2cs35032g ↗
17. 10.1021/am302528g10.1021/am302528g ↗
18. 10.1021/la301007910.1021/la3010079 ↗
19. 10.1371/journal.pone.001592710.1371/journal.pone.0015927 ↗
20. 10.4049/jimmunol.130136510.4049/jimmunol.1301365 ↗
21. 10.1371/journal.pone.012377210.1371/journal.pone.0123772 ↗
22. 10.4049/jimmunol.080274010.4049/jimmunol.0802740 ↗
23. 10.1097/SLA.000000000000178310.1097/SLA.0000000000001783 ↗
24. 10.3389/fimmu.2019.0032710.3389/fimmu.2019.00327 ↗
25. 10.2119/molmed.2010.0017810.2119/molmed.2010.00178 ↗
26. 10.3389/fimmu.2019.0091710.3389/fimmu.2019.00917 ↗
27. 10.4049/jimmunol.090266110.4049/jimmunol.0902661 ↗
28. 10.1186/2051-1426-1-1010.1186/2051-1426-1-10 ↗
29. 10.1128/IAI.00239-1210.1128/IAI.00239-12 ↗
30. 10.1158/0008-5472.CAN-13-154510.1158/0008-5472.CAN-13-1545 ↗
31. 10.1158/0008-5472.CAN-09-369010.1158/0008-5472.CAN-09-3690 ↗
32. 10.1182/blood-2011-07-36582510.1182/blood-2011-07-365825 ↗
33. 10.1002/cam4.18610.1002/cam4.186 ↗
34. 10.1189/jlb.021205910.1189/jlb.0212059 ↗
35. 10.1136/annrheumdis-2016-20978610.1136/annrheumdis-2016-209786 ↗
36. Sukhatme, Vikas P.; Husain, Z. Cancer Therapy Targeting Tetraspanin 33 (Tspan33) in Myeloid Derived Suppressor Cells. WO 2016/210241 Al, 2016.
37. 10.1016/j.clim.2013.08.00510.1016/j.clim.2013.08.005 ↗
38. 10.1038/nm.356010.1038/nm.3560 ↗
39. 10.1038/nrc389310.1038/nrc3893 ↗
40. 10.1038/ncomms1215010.1038/ncomms12150 ↗
41. 10.4049/jimmunol.181.7.466610.4049/jimmunol.181.7.4666 ↗
42. 10.1111/j.1365-2567.2012.03566.x10.1111/j.1365-2567.2012.03566.x ↗
43. 10.1096/fj.08-11706910.1096/fj.08-117069 ↗
44. 10.1021/ja509513c10.1021/ja509513c ↗
45. 10.1021/acs.nanolett.8b0330510.1021/acs.nanolett.8b03305 ↗
46. 10.7150/thno.3254610.7150/thno.32546 ↗
47. 10.1007/s10439-011-0449-410.1007/s10439-011-0449-4 ↗
48. 10.1039/C7TB00150A10.1039/C7TB00150A ↗
49. 10.1142/S179398441341001810.1142/S1793984413410018 ↗
50. 10.1371/journal.pone.006098910.1371/journal.pone.0060989 ↗
51. 10.4049/jimmunol.140230110.4049/jimmunol.1402301 ↗
52. 10.1016/j.injury.2007.08.04110.1016/j.injury.2007.08.041 ↗
53. Cheng L. · Int. J. Clin. Exp. Pathol. · 2017 · 10 · 11063
54. 10.1016/j.biomaterials.2020.12040510.1016/j.biomaterials.2020.120405 ↗
55. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
56. 10.1021/nn507025910.1021/nn5070259 ↗
57. 10.3390/molecules1601085710.3390/molecules16010857 ↗
58. 10.1038/nrd.2016.19910.1038/nrd.2016.199 ↗
59. 10.4161/mabs.2724010.4161/mabs.27240 ↗
60. 10.1073/pnas.110535110810.1073/pnas.1105351108 ↗
61. 10.1038/cgt.2013.8110.1038/cgt.2013.81 ↗
62. 10.1371/journal.pone.004067710.1371/journal.pone.0040677 ↗
63. 10.1073/pnas.141149911110.1073/pnas.1411499111 ↗
64. 10.1111/j.1600-0854.2012.01382.x10.1111/j.1600-0854.2012.01382.x ↗
65. 10.1126/scitranslmed.aaf941810.1126/scitranslmed.aaf9418 ↗
66. 10.1073/pnas.100824810710.1073/pnas.1008248107 ↗
67. 10.1155/2014/59865410.1155/2014/598654 ↗
68. 10.1007/s00018-019-03048-x10.1007/s00018-019-03048-x ↗